Clinical outcome of routine treatment of patients with Pelvic Inflammatory Disease and/or Tubo Ovarial Abcess in the presence or absence of Mycoplasma genitalium (MG)

Recruiting

• Conditions: PID; 10028474; 10033283

• Registration Number: NL-OMON54533
• Lead Sponsor: GGD Amsterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

Patients with PID or TOA

Exclusion Criteria

Pregnancy
Hypersensitivity to antibiotics given as standard treatment
Not being able to understand information provided in Dutch or English

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Clinical outcome of PID and/or TOA is based on fever, abdominal pain, cervical<br /><br>leucorrhoea during speculum examination, painful genitalia interna, other<br /><br>clinical signs and CRP.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) The presence and persistence of MG-DNA in vaginal swabs.<br /><br>2) Antibiotic resistance prevalence in MG positive cases.</p><br>